Autolus Therapeutics (AUTL) Operating Income (2018 - 2026)
Autolus Therapeutics' (AUTL) quarterly Operating Income came in at -$72.5 million in Q4 2025, up 4.48% YoY from -$69.4 million in Q4 2024, and down 1.18% on a QoQ basis from -$71.6 million in Q3 2025.
Autolus Therapeutics (AUTL) Operating Income (2018 - 2026) Analysis & Trends
Autolus Therapeutics (AUTL) has 8 years of Operating Income data on file, last reported at -$72.5 million in Q4 2025.
- Quarterly Operating Income rose 4.48% year-over-year to -$72.5 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was -$270.5 million (down 12.06% YoY) and the FY2025 annual result came in at -$270.5 million, down 12.06% from the prior year.
- Operating Income declined to -$72.5 million in Q4 2025, from -$71.6 million in the prior quarter.
- In the past five years, Operating Income ranged from a high of -$11.6 million in Q4 2022 to a low of -$75.9 million in Q4 2024.
- A 5-year average of -$47.8 million and a median of -$41.6 million in 2021 frame the typical range for Operating Income.
- Annual changes were most pronounced in 2021 — Operating Income surged 51.19% — and 2023, when it slumped 357.26%.
- Tracing AUTL's Operating Income over 5 years: stood at -$23.1 million in 2021, then jumped by 49.57% to -$11.6 million in 2022, then slumped by 357.26% to -$53.3 million in 2023, then sank by 42.41% to -$75.9 million in 2024, then increased by 4.48% to -$72.5 million in 2025.
- The last three Operating Income figures came in at -$72.5 million (Q4 2025), -$71.6 million (Q3 2025), and -$61.2 million (Q2 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Op. Inc (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 1.25 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 1.29 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 493.00 Mn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | -505.13 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 325.05 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -3,158.03 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 133.12 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 231.44 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -1.55 Mn |
| 10 | Autolus Therapeutics | 763.37 Mn | 561.74 Mn | 25.22 Mn | -43.84 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -43.84 Mn |
| Dec 31, 2025 | -72.47 Mn |
| Sep 30, 2025 | -71.62 Mn |
| Jun 30, 2025 | -61.22 Mn |
| Mar 31, 2025 | -65.24 Mn |
| Dec 31, 2024 | -75.86 Mn |
| Sep 30, 2024 | -67.88 Mn |
| Jun 30, 2024 | -58.93 Mn |
| Mar 31, 2024 | -38.76 Mn |
| Dec 31, 2023 | -53.27 Mn |
| Sep 30, 2023 | -42.91 Mn |
| Jun 30, 2023 | -44.38 Mn |
| Mar 31, 2023 | -39.15 Mn |
| Dec 31, 2022 | -11.65 Mn |
| Sep 30, 2022 | -37.35 Mn |
| Jun 30, 2022 | -39.06 Mn |
| Mar 31, 2022 | -36.19 Mn |
| Dec 31, 2021 | -23.10 Mn |
| Sep 30, 2021 | -40.36 Mn |
| Jun 30, 2021 | -37.72 Mn |